Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Dr Schär
Mandate

Vinge advised Dr Schär

February 29, 2024 M&A EU, Competition and Regulatory

Vinge advised Dr Schär in the acquisition of Semper AB:s glutenfree business Dr. Schär, an Italian based company, is a developer of product for special nutritional needs.

Vinge advised Dr. Schär in its acquisition of Semper AB's gluten free business in the Nordics. Vinge's team was headed by Wibeke Sorling (Partner, M&A) and consisted mainly of a team managed by Anna Palmérus (Partner, EU & Competition law), Jenny Sandlund (Senior associate, M&A) and Victoria Gunnerek (Senior Associate, EU & Competition law).

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

 Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

 Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025